Premium
Pharmacokinetic interaction studies between felbamate and vigabatrin.
Author(s) -
Reidenberg P.,
Glue P.,
Banfield C.,
Colucci R.,
Meehan J.,
Rey E.,
Radwanski E.,
Nomeir A.,
Lim J.,
Lin C.
Publication year - 1995
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1995.tb05770.x
Subject(s) - felbamate , vigabatrin , pharmacokinetics , anticonvulsant , placebo , crossover study , pharmacology , medicine , anesthesia , epilepsy , alternative medicine , pathology , psychiatry
To assess the possible occurrence of pharmacokinetic interactions between the antiepileptic agents felbamate and vigabatrin, two randomized, double‐blind, placebo‐controlled, crossover studies were conducted in healthy male volunteers. In Study I, 18 subjects received oral vigabatrin 1000 mg every 12 h for two 8 days periods with felbamate 1200 mg every 12 h or placebo. In Study II, 18 other volunteers were administered oral felbamate 1200 mg every 12 h for two 8 days periods with vigabatrin 1000 mg every 12 h or placebo. On the eighth day of each treatment period, blood and urine samples were collected over 12 h for determination of the active S(+)‐ and inactive R(−)−vigabatrin enantiomer concentrations (Study I) or felbamate concentrations (Study II). In Study I, the pharmacokinetic parameters of R(−)−vigabatrin were similar during co‐administration with felbamate or placebo. Felbamate produced a 13% increase in AUC(0.12 h) and an 8% increase in urinary excretion of S(+)‐vigabatrin. Although these changes were statistically significant, their magnitude was small. In Study II, the pharmacokinetic parameters of felbamate were similar during concurrent administration with vigabatrin or placebo. These data indicate that there are no clinically relevant pharmacokinetic interactions between felbamate and vigabatrin in man.